Foghorn Therapeutics Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $30.9M | $22.6M | $34.2M | $19.2M | $1.3M |
| Research and development | $85.5M | $94.5M | $109.7M | $105.6M | $80.3M |
| Operating expenses | $117.3M | $125.3M | $142.1M | $136.4M | $102.1M |
| Operating income | -$86.4M | -$102.7M | -$107.9M | -$117.1M | -$100.7M |
| Interest expense | — | — | — | — | $1.9M |
| Pretax income | — | -$86.6M | -$94.2M | -$108.9M | — |
| Income tax expense | $0 | $0 | $4.2M | $0 | — |
| Net income | -$74.3M | -$86.6M | -$98.4M | -$108.9M | -$101.3M |
| Balance Sheet | |||||
| Cash and equivalents | $80.9M | $55.5M | $80.3M | $52.2M | $101.1M |
| Current assets | $163.2M | $249.6M | $240.2M | $351.4M | $459.6M |
| Total assets | $198.1M | $284.0M | $285.9M | $404.9M | $519.8M |
| Current liabilities | $59.7M | $67.0M | $58.4M | $55.2M | $48.7M |
| Total liabilities | $306.6M | $329.5M | $363.1M | $404.8M | $422.9M |
| Stockholders' equity | -$108.5M | -$45.5M | -$77.2M | $112,000 | $96.9M |
| Cash Flow Statement | |||||
| Cash from operations | -$86.1M | -$100.4M | -$118.1M | $193.6M | -$50.2M |
| Depreciation and amortization | $3.3M | $3.1M | $3.5M | $3.3M | $3.2M |
| Stock-based compensation | $10.4M | $11.9M | $16.2M | $14.3M | $8.4M |
| Capital expenditure | $50,000 | $906,000 | $1.2M | $1.2M | $3.3M |
| Free cash flow | -$86.1M | -$101.3M | -$119.3M | $192.4M | -$53.6M |
| Impairments | — | — | $0 | $0 | $0 |
Shares outstanding 58.7M · Free float 67.6%
Annual filing data through FY ended December 31, 2025; float as of July 15, 2026.